Drugs in development for chronic hepatitis C: a promising future

Bibliography

• Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29(Suppl 1):74-81
   PubMed Web of Science ®Google Scholar
• Davis GL, Alter MJ, El-Serag H, Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138:513-21; 521e1–6
   PubMed Web of Science ®Google Scholar
• Prescribing Information for INCIVEK™ (telaprevir); Vertex Pharmaceuticals Incorporated. Issued 5/11 [package insert]
   Google Scholar
• Prescribing Information for VICTRELIS™ (boceprevir); Schering Corporation, a subsidiary of Merck & Co., Inc. Issued 5/11 [package insert]
   Google Scholar
• Lok A, Gardiner D, Lawitz E, Quadruple therapy with BMS-790052, BMS-650032 and PEG-IFN/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders. J Hepatol 2011;54(Suppl 1):S536
   Google Scholar
• Ge D, Fellay J, Thompson AJ, Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Muir AJ, Sulkowski MS, Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype. Hepatology 2010;52:2243-4
   PubMed Web of Science ®Google Scholar
• Grebely J, Petoumenos K, Hellard M, Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010;52:1216-24
   PubMed Web of Science ®Google Scholar
• Poordad F, Bronowicki JP, Gordon SC, IL-28 B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with bocepravir combination therapy. J Hepatol 2011;54(Suppl 1):S6
   Web of Science ®Google Scholar
• Pol S, Aerssens J, Zeuzem S, Similar SVR rates in IL28B CC, CT or TT Prior Relapser, Partial- or Null-responder patients treated with Telaprevir/Peginterferon/Ribavirin: retrospective analysis of the REALIZE Study. J Hepatol 2011;54(Suppl 1):S6
   PubMedGoogle Scholar
• LabCorp launches interleukin-28 polymorphism (IL28B) genotype test to support individualized treatment decisions for patients with hepatitis C viral infection. LabCorp Service Announcement.2010 Jul 12. Available from: http://www.labcorp.com
   Google Scholar
• Thompson AJ, Fellay J, Patel K, Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 2010;139:1181-9
   PubMed Web of Science ®Google Scholar
• Roche receives FDA approval for a second-generation hepatitis C viral load test. Pleasanton, CA: Roche Molecular Laboratories, 2010. Available from: http://www.roche.com/med_dia_2010-09-22 [Last accessed 29 September 2011]
   Google Scholar
• Release of information from Frequency and Clinical Relevance of Detectable/<LLOQ HCV RNA in Boceprevir and Telaprevir Trials by Patrick Harrington, Ph.D. and Lisa Naeger, Ph.D., Clinical Virology Reviewers FDA Division of Antiviral Products June 30, 2011. [6th International Workshop on Hepatitis C-Resistance and New Compounds; Boston, MA, 23-24 June 2011]
   Google Scholar
• Pawlotsky JM. Virology of hepatitis B and C viruses and antiviral targets. J Hepatol 2006;44:S10-13
   PubMedGoogle Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16
   PubMed Web of Science ®Google Scholar
• Sherman KE, Flamm SL, Afdhal NH, Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-24
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Manns MP, Muir AJ, Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010;362:1292-303
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Andreone P, Pol S, Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:1-12
   PubMedGoogle Scholar
• Foster RF, Hezode C, Bronowicki J-P, Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011;141:881-9
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J, Bacon BR, Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206
   PubMed Web of Science ®Google Scholar
• Bacon BR, Gordon SC, Lawitz E, Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Sulkowski MS, Zoulim F, Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2A and ribavirin: interim analysis of the EXTEND study [abstract]. Hepatology 2010;52(Suppl S1):436A
   Google Scholar
• Sullivan JC, De Meyer S, Bartels DJ, Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. J Hepatol 2011;54(Suppl 1):S4
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010;138:447-62
   PubMed Web of Science ®Google Scholar
• Pockros P, Jensen D, Tsai N, First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon/ribavirin in treatment-naive HCV G1/4 patients: interim analysis from the JUMP-C trial. J Hepatol 2011;54(Suppl 1):S538
   Google Scholar
• Gane EJ, Roberts SK, Stedman CA, Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010;376:1467-75
   PubMed Web of Science ®Google Scholar
• Nelson DR, Lalezari J, Lawitz E, PSI-7977 QD Plus PEG/RBV In HCV GT1: 98% rapid virologic response complete early virologic response: the PROTON Study [abstract 1372]. J Hepatol 2011;54(Suppl 1):S544
   Google Scholar
• Lawitz E, Rodriguez-Torres M, Denning J, Once daily dual-nucleoside combination of PSI-938 and PSI-7977 provides 94% HCV RNA<LOD at Day 14: first purine/pyrimadine clinical combination data (The NUCLEAR Study) [abstract 61]. J Hepatol 2011;54(Suppl 1):S28
   Google Scholar
• Gilead amends study design for ongoing hepatitis C clinical trials that include GS 9190, pegylated interferon and ribavirin, and another direct-acting antiviral agent. Foster City, CA: Gilead Sciences, Inc., 2011. Available from: http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&id=1603474 [Last accessed 29 September 2011]
   Google Scholar
• Zeuzem S, Buggisch P, Agarwal K, Dual, Triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PEGIFN/RBV for up to 28 days in treatment-naive, genotype 1 HCV subjects. Hepatology 2010;52(Suppl S1):LB1
   Google Scholar
• Asselah T. NS5A inhibitors: a new breakthrough for the treatment of chronic hepatitis C. J Hepatol 2011;54:1069-72
   PubMed Web of Science ®Google Scholar
• Hezode C, Hirschfield GM, Ghesquiere W, BMS-790052, A NS5A replication complex inhibitor, combined with peginterferon-alfa-2a and ribavirin in treatment-naive HCV-genotype 1 or 4 subjects: phase 2b AI444010 Study Interim Week 12 results. 62nd AASLD Meeting; 4 – 8 November 2011; San Francisco, California [www.aasld.org]
   Google Scholar
• Flisiak R, Feinman SV, Jablkowski M, The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 2009;49:1460-8
   PubMed Web of Science ®Google Scholar
• Gallay PA. Cyclophilin inhibitors. Clin Liver Dis 2009;13:403-17
   PubMed Web of Science ®Google Scholar
• Guedj J, Rong L, Dahari H, A perspective on modeling hepatitis C virus infection. J Viral Hepat 2010;17:825-33
   PubMed Web of Science ®Google Scholar
• Struble K. Clinical trials design: experimental HCV drugs for HIV/HCV co-infected people: FDA perspectives on clinical trial design for new HCV products, early access. European AIDS Treatment Group Meeting; 21 Nov 2009; Brussels. Avaialble from http://www.eatg.org/eatg/Scientific-Research/Conferences/Brussels-I-Sitges-III-Nov-20-2009-Brussels [Last accessed 29 September 2011]
   Google Scholar
• Marcellin P, Forns X, Goeser T, Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011;140:459-68; e1
   PubMed Web of Science ®Google Scholar
• The 61st Annual Meeting of the American Association for the Study of Liver Diseases: the Liver Meeting 2010. Hepatology 2010; 52(Suppl S1): selected abstracts as listed in Table 4.
   Google Scholar